Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Maplirpacept · 2 trials · 3 indications
Part A only. To characterize the dose limiting toxicities (DLTs) of Maplirpacept.
Maximum Observed Plasma Concentration
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 1 week.
Number of participants with DLTs
| Arm | Type | Description |
|---|---|---|
| Maplirpacept (PF-07901801) | EXPERIMENTAL | single arm study |
| Name | Type | Description |
|---|---|---|
| Maplirpacept | DRUG | Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles. |
| maplirpacept (PF-07901801) | DRUG | maplirpacept (PF-07901801) |
Key Inclusion Criteria: * Histologically confirmed relapsed/refractory non-Hodgkin lymphoma without other effective therapeutic option. Or relapsed/refractory multiple myeloma exposed to therapies including PI, IMiD and anti-CD38 antibody. * With measurable disease * Eastern Cooperative Oncology Gr...
Maplirpacept is an investigational small molecule being studied for the treatment of hematologic malignancies, specifically Non-Hodgkin Lymphoma and Lymphoma. It is also being evaluated in patients with Multiple Myeloma. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Maplirpacept is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for the treatment of hematologic malignancies.
Maplirpacept is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in early-stage trials to evaluate its safety and tolerability in patients with Non-Hodgkin Lymphoma and other hematologic malignancies.
Maplirpacept has been studied in two completed Phase 1 clinical trials. NCT05567887 evaluated the drug in Japanese patients with Lymphoma and Multiple Myeloma, enrolling 7 participants. NCT05896774 studied the drug in Chinese patients with Non-Hodgkin Lymphoma and Multiple Myeloma, enrolling 10 participants. Both trials were uncontrolled and not randomized.
Yes, Maplirpacept is also known as PF-07901801. Clinical trial NCT05567887 refers to the study medicine as Maplirpacept (PF-07901801), confirming that these names refer to the same investigational drug being developed by Pfizer.